All In Biotech

Drug Trial Radar · NCT05127525

EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)

Randomized, Double-Masked, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of IRX-101 Versus 5% Povidone-Iodine as an Ocular Surface Sterilizer

Last checked: Nov 19, 2026Latest source record: May 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

5

Actual

Start

Nov 15, 2021

Primary completion

Jan 31, 2022

Study completion Jan 31, 2022

Sponsor

Lead sponsor
iRenix Medical, Inc.Industry
Sponsor type
Industry
First posted
Nov 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-masked, multicenter, study to evaluate the efficacy, safety, and tolerability of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections. The study will be conducted in up to 30 centers in the United States (US).

Conditions

  • Diabetic Macular Edema
  • Branch Retinal Vein Occlusion
  • Glaucoma/Closed Angle Glaucoma

Interventions

  • IRX-101Drug

    IRX-101 to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)

  • ControlDrug

    Providone-Iodine Betadine to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of infectious endophthalmitis after topical use of IRX-101 combined with IVTTime frame: 2 hours post-injection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Florida

    Tampa, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.